Playback speed
10 seconds
ANCO's ASCO 2019 Update On PARP Inhibitors In Ovarian Cancer: Niraparib + Bevacizumab Improves PFS In Recurrent Ovarian Cancer & Olaparib Monotherapy Extends PFS In Germline BRCA1/2-mutated Ovarian Cancer
By
ANCO’s ASCO Highlights 2019
FEATURING
Rebecca Brooks
By
ANCO’s ASCO Highlights 2019
FEATURING
Rebecca Brooks
317 views
September 12, 2019
Login to view comments.
Click here to Login